Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia

Adverse genetic risk acute myeloid leukemia (AML) includes a wide range of clinical-pathological entities with extremely poor outcomes; thus, novel therapeutic approaches are needed. Promising results achieved by engineered chimeric antigen receptor (CAR) T cells in other blood neoplasms have paved...

Descripción completa

Detalles Bibliográficos
Autores principales: Limongello, Roberto, Marra, Andrea, Mancusi, Antonella, Bonato, Samanta, Hoxha, Eni, Ruggeri, Loredana, Hui, Susanta, Velardi, Andrea, Pierini, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8368440/
https://www.ncbi.nlm.nih.gov/pubmed/34413848
http://dx.doi.org/10.3389/fimmu.2021.695051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8368440/
https://www.ncbi.nlm.nih.gov/pubmed/34413848
http://dx.doi.org/10.3389/fimmu.2021.695051

Ejemplares similares